Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 107

1.

Importance of osteoprotegrin and receptor activator of nuclear factor κB in breast cancer response to hepatocyte growth factor and the bone microenvironment in vitro.

Owen S, Sanders AJ, Mason MD, Jiang WG.

Int J Oncol. 2016 Mar;48(3):919-28. doi: 10.3892/ijo.2016.3339. Epub 2016 Jan 15.

PMID:
26781475
2.

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.

James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, Ritchie AW, Parker CC, Russell JM, Attard G, de Bono J, Cross W, Jones RJ, Thalmann G, Amos C, Matheson D, Millman R, Alzouebi M, Beesley S, Birtle AJ, Brock S, Cathomas R, Chakraborti P, Chowdhury S, Cook A, Elliott T, Gale J, Gibbs S, Graham JD, Hetherington J, Hughes R, Laing R, McKinna F, McLaren DB, O'Sullivan JM, Parikh O, Peedell C, Protheroe A, Robinson AJ, Srihari N, Srinivasan R, Staffurth J, Sundar S, Tolan S, Tsang D, Wagstaff J, Parmar MK; STAMPEDE investigators.

Lancet. 2015 Dec 21. pii: S0140-6736(15)01037-5. doi: 10.1016/S0140-6736(15)01037-5. [Epub ahead of print]

3.

Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data.

Vale CL, Burdett S, Rydzewska LH, Albiges L, Clarke NW, Fisher D, Fizazi K, Gravis G, James ND, Mason MD, Parmar MK, Sweeney CJ, Sydes MR, Tombal B, Tierney JF; STOpCaP Steering Group.

Lancet Oncol. 2016 Feb;17(2):243-56. doi: 10.1016/S1470-2045(15)00489-1. Epub 2015 Dec 21.

4.

Role of Hormonal Treatment in Prostate Cancer Patients with Nonmetastatic Disease Recurrence After Local Curative Treatment: A Systematic Review.

van den Bergh RC, van Casteren NJ, van den Broeck T, Fordyce ER, Gietzmann WK, Stewart F, MacLennan S, Dabestani S, Bellmunt J, Bolla M, Briers E, Cornford P, Joniau S, Mason MD, Matveev V, van der Poel HG, van der Kwast TH, Rouvière O, Wiegel T, Lam TB, Mottet N.

Eur Urol. 2015 Dec 12. pii: S0302-2838(15)01178-1. doi: 10.1016/j.eururo.2015.11.023. [Epub ahead of print] Review.

PMID:
26691493
5.

Traditional Chinese medicine in the prevention and treatment of cancer and cancer metastasis.

Ye L, Jia Y, Ji KE, Sanders AJ, Xue K, Ji J, Mason MD, Jiang WG.

Oncol Lett. 2015 Sep;10(3):1240-1250. Epub 2015 Jul 6.

6.

Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial.

James ND, Spears MR, Clarke NW, Dearnaley DP, Mason MD, Parker CC, Ritchie AW, Russell JM, Schiavone F, Attard G, de Bono JS, Birtle A, Engeler DS, Elliott T, Matheson D, O'Sullivan J, Pudney D, Srihari N, Wallace J, Barber J, Syndikus I, Parmar MK, Sydes MR; STAMPEDE Investigators.

JAMA Oncol. 2015 Nov 25:1-10. doi: 10.1001/jamaoncol.2015.4350. [Epub ahead of print]

PMID:
26606329
7.

EPLIN: a fundamental actin regulator in cancer metastasis?

Collins RJ, Jiang WG, Hargest R, Mason MD, Sanders AJ.

Cancer Metastasis Rev. 2015 Dec;34(4):753-64. doi: 10.1007/s10555-015-9595-8.

8.

YangZheng XiaoJi exerts anti-tumour growth effects by antagonising the effects of HGF and its receptor, cMET, in human lung cancer cells.

Jiang WG, Ye L, Ruge F, Owen S, Martin T, Sun PH, Sanders AJ, Lane J, Satherley L, Weeks HP, Gao Y, Wei C, Wu Y, Mason MD.

J Transl Med. 2015 Aug 27;13:280. doi: 10.1186/s12967-015-0639-1.

9.

Cardiovascular effects of hormone therapy for prostate cancer.

Lester JF, Mason MD.

Drug Healthc Patient Saf. 2015 Jul 23;7:129-38. doi: 10.2147/DHPS.S50549. eCollection 2015. Review.

10.

Impact of Radiotherapy When Added to Androgen-Deprivation Therapy for Locally Advanced Prostate Cancer: Long-Term Quality-of-Life Outcomes From the NCIC CTG PR3/MRC PR07 Randomized Trial.

Brundage M, Sydes MR, Parulekar WR, Warde P, Cowan R, Bezjak A, Kirkbride P, Parliament M, Moynihan C, Bahary JP, Parmar MK, Sanders K, Chen BE, Mason MD.

J Clin Oncol. 2015 Jul 1;33(19):2151-7. doi: 10.1200/JCO.2014.57.8724. Epub 2015 May 26.

PMID:
26014295
11.

Tumor stroma-derived factors skew monocyte to dendritic cell differentiation toward a suppressive CD14+ PD-L1+ phenotype in prostate cancer.

Spary LK, Salimu J, Webber JP, Clayton A, Mason MD, Tabi Z.

Oncoimmunology. 2014 Dec 13;3(9):e955331. eCollection 2014 Oct.

12.

Expression of Sonic Hedgehog (SHH) in human lung cancer and the impact of YangZheng XiaoJi on SHH-mediated biological function of lung cancer cells and tumor growth.

Jiang WG, Ye L, Ruge F, Sun PH, Sanders AJ, Ji K, Lane J, Zhang L, Satherley L, Weeks HP, Zhi X, Gao Y, Wei C, Wu Y, Mason MD.

Anticancer Res. 2015 Mar;35(3):1321-31.

PMID:
25750281
13.

Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer.

Mason MD, Parulekar WR, Sydes MR, Brundage M, Kirkbride P, Gospodarowicz M, Cowan R, Kostashuk EC, Anderson J, Swanson G, Parmar MK, Hayter C, Jovic G, Hiltz A, Hetherington J, Sathya J, Barber JB, McKenzie M, El-Sharkawi S, Souhami L, Hardman PD, Chen BE, Warde P.

J Clin Oncol. 2015 Jul 1;33(19):2143-50. doi: 10.1200/JCO.2014.57.7510. Epub 2015 Feb 17.

14.

Cross-Presentation of the Oncofetal Tumor Antigen 5T4 from Irradiated Prostate Cancer Cells--A Key Role for Heat-Shock Protein 70 and Receptor CD91.

Salimu J, Spary LK, Al-Taei S, Clayton A, Mason MD, Staffurth J, Tabi Z.

Cancer Immunol Res. 2015 Jun;3(6):678-88. doi: 10.1158/2326-6066.CIR-14-0079. Epub 2015 Feb 12.

PMID:
25678582
15.

Final quality of life and safety data for patients with metastatic castration-resistant prostate cancer treated with cabazitaxel in the UK Early Access Programme (EAP) (NCT01254279).

Bahl A, Masson S, Malik Z, Birtle AJ, Sundar S, Jones RJ, James ND, Mason MD, Kumar S, Bottomley D, Lydon A, Chowdhury S, Wylie J, de Bono JS.

BJU Int. 2015 Dec;116(6):880-7. doi: 10.1111/bju.13069. Epub 2015 Jun 16.

PMID:
25639506
16.

Cancer exosomes trigger mesenchymal stem cell differentiation into pro-angiogenic and pro-invasive myofibroblasts.

Chowdhury R, Webber JP, Gurney M, Mason MD, Tabi Z, Clayton A.

Oncotarget. 2015 Jan 20;6(2):715-31.

17.

Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).

James ND, Spears MR, Clarke NW, Dearnaley DP, De Bono JS, Gale J, Hetherington J, Hoskin PJ, Jones RJ, Laing R, Lester JF, McLaren D, Parker CC, Parmar MK, Ritchie AW, Russell JM, Strebel RT, Thalmann GN, Mason MD, Sydes MR.

Eur Urol. 2015 Jun;67(6):1028-38. doi: 10.1016/j.eururo.2014.09.032. Epub 2014 Oct 6.

18.

Implication of metastasis suppressor gene, Kiss-1 and its receptor Kiss-1R in colorectal cancer.

Ji K, Ye L, Ruge F, Hargest R, Mason MD, Jiang WG.

BMC Cancer. 2014 Sep 27;14:723. doi: 10.1186/1471-2407-14-723.

19.

Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial.

Lane JA, Donovan JL, Davis M, Walsh E, Dedman D, Down L, Turner EL, Mason MD, Metcalfe C, Peters TJ, Martin RM, Neal DE, Hamdy FC; ProtecT study group.

Lancet Oncol. 2014 Sep;15(10):1109-18. doi: 10.1016/S1470-2045(14)70361-4. Epub 2014 Aug 19. Erratum in: Lancet Oncol. 2014 Oct;15(11):e475.

20.

Therapeutic potential of capillary morphogenesis gene 2 extracellular vWA domain in tumour‑related angiogenesis.

Ye L, Sun PH, Sanders AJ, Martin TA, Lane J, Mason MD, Jiang WG.

Int J Oncol. 2014 Oct;45(4):1565-73. doi: 10.3892/ijo.2014.2533. Epub 2014 Jul 3.

PMID:
24993339
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk